Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

13.3%

2 terminated out of 15 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

15Total
P 1 (15)

Trial Status

Recruiting6
Active Not Recruiting3
Not Yet Recruiting2
Unknown2
Terminated2

Clinical Trials (15)

Showing 15 of 15 trials
NCT07023731Phase 1Recruiting

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

NCT05947474Phase 1Active Not RecruitingPrimary

ORB-011 In Patients With Advanced Solid Tumors

NCT07265921Phase 1RecruitingPrimary

A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

NCT07123415Phase 1RecruitingPrimary

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT07196579Phase 1Not Yet RecruitingPrimary

Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

NCT06985355Phase 1RecruitingPrimary

A Study of MHB046C Injection in Patients With Advanced Solid Tumors

NCT07088588Phase 1Not Yet RecruitingPrimary

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

NCT06666270Phase 1RecruitingPrimary

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

NCT03917043Phase 1RecruitingPrimary

APG-2449 in Patients With Advanced Solid Tumors

NCT04877717Phase 1Active Not RecruitingPrimary

A Study of SHR-A1904 in Patients With Advanced Solid Cancer

NCT03791112Phase 1Active Not RecruitingPrimary

A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor

NCT03884517Phase 1TerminatedPrimary

Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer

NCT05770310Phase 1UnknownPrimary

A Phase I Study Of JS015 in Patients With Advanced Solid Tumors

NCT03618043Phase 1UnknownPrimary

Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer

NCT01416623Phase 1TerminatedPrimary

A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies

Showing all 15 trials

Research Network

Activity Timeline